Clinical trial
TELEHEART: Telotristat Ethyl in a Heart Biomarker Study
NCT04810091 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TELEHEART: Telotristat Ethyl in a Heart Biomarker Study
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- May 18, 2021
- Completion date
- August 3, 2026
- Enrollment
- 79 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced neuroendocrine neoplasm, metastatic neuroendocrine neoplasm